FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946988148> ?p ?o ?g. }

• W2946988148 endingPage "267" @default.
• W2946988148 startingPage "259" @default.
• W2946988148 abstract "Lung cancer resulted in an estimated 1.8 million deaths worldwide in 2018 and approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III unresectable disease. Phase III data from the PACIFIC trial show significantly improved progression-free survival for the checkpoint-inhibitor durvalumab given as consolidation following definitive chemoradiotherapy (cCRT). Overall survival results from this study have now been reported, along with outcomes from other phase II trials. A thorough review of the efficacy and safety of checkpoint-inhibitors used in conjunction with cCRT for stage III unresectable NSCLC is needed. Published and presented literature on phase II and III data was identified using the key search terms non-small cell lung cancer AND checkpoint-inhibitors (OR respective aliases). One randomized phase III clinical trial and three phase II trials reporting outcomes of checkpoint-inhibitors in conjunction with cCRT for stage III unresectable NSCLC were identified. PACIFIC reported significantly improved overall survival for consolidation durvalumab following cCRT compared with placebo. Although discontinuation due to adverse events (AEs) was higher with durvalumab, rates of grade 3/4 pneumonitis or radiation pneumonitis were low and comparable between arms. Results from phase II trials also show promising activity for other checkpoint-inhibitors and alternative sequencing strategies, although these need to be confirmed in a randomized context. Preliminary data suggest differences in the safety profiles between PD-1 and PD-L1 inhibitors. Currently, the role of PD-L1 expression levels for patient selection in this setting remains unclear, and durvalumab should be administered on an individual basis in patients with known driver mutations. Consolidation durvalumab following cCRT significantly improves overall survival with an acceptable safety profile in patients with stage III unresectable NSCLC, now representing a new standard of care." @default.
• W2946988148 created "2019-06-07" @default.
• W2946988148 creator A5006433317 @default.
• W2946988148 creator A5009144321 @default.
• W2946988148 creator A5012748795 @default.
• W2946988148 creator A5046566606 @default.
• W2946988148 creator A5080668859 @default.
• W2946988148 creator A5082061757 @default.
• W2946988148 creator A5087116862 @default.
• W2946988148 date "2019-08-01" @default.
• W2946988148 modified "2023-09-27" @default.
• W2946988148 title "Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer" @default.
• W2946988148 cites W1944220675 @default.
• W2946988148 cites W1968899146 @default.
• W2946988148 cites W1977912929 @default.
• W2946988148 cites W1982488143 @default.
• W2946988148 cites W2003456733 @default.
• W2946988148 cites W2022837929 @default.
• W2946988148 cites W2046749626 @default.
• W2946988148 cites W2052727153 @default.
• W2946988148 cites W2066671159 @default.
• W2946988148 cites W2096322385 @default.
• W2946988148 cites W2098564635 @default.
• W2946988148 cites W2101653483 @default.
• W2946988148 cites W2104347254 @default.
• W2946988148 cites W2104701073 @default.
• W2946988148 cites W2110469369 @default.
• W2946988148 cites W2122495232 @default.
• W2946988148 cites W2122940327 @default.
• W2946988148 cites W2123291375 @default.
• W2946988148 cites W2140469315 @default.
• W2946988148 cites W2149089484 @default.
• W2946988148 cites W2152939220 @default.
• W2946988148 cites W2153169173 @default.
• W2946988148 cites W2156353875 @default.
• W2946988148 cites W2159094759 @default.
• W2946988148 cites W2160834915 @default.
• W2946988148 cites W2171419394 @default.
• W2946988148 cites W2228221433 @default.
• W2946988148 cites W2231752536 @default.
• W2946988148 cites W2337507927 @default.
• W2946988148 cites W2486385287 @default.
• W2946988148 cites W2527905628 @default.
• W2946988148 cites W2528393079 @default.
• W2946988148 cites W2566833162 @default.
• W2946988148 cites W2566863750 @default.
• W2946988148 cites W2567564314 @default.
• W2946988148 cites W2612420308 @default.
• W2946988148 cites W2618641368 @default.
• W2946988148 cites W2625188669 @default.
• W2946988148 cites W2635951006 @default.
• W2946988148 cites W2643935873 @default.
• W2946988148 cites W2745126191 @default.
• W2946988148 cites W2749840721 @default.
• W2946988148 cites W2753065806 @default.
• W2946988148 cites W2756648224 @default.
• W2946988148 cites W2768434280 @default.
• W2946988148 cites W2791567488 @default.
• W2946988148 cites W2791886669 @default.
• W2946988148 cites W2797448299 @default.
• W2946988148 cites W2797744035 @default.
• W2946988148 cites W2805354595 @default.
• W2946988148 cites W2886119834 @default.
• W2946988148 cites W2889646458 @default.
• W2946988148 cites W2889797672 @default.
• W2946988148 cites W2890230299 @default.
• W2946988148 cites W2891004049 @default.
• W2946988148 cites W2893824814 @default.
• W2946988148 cites W2897819498 @default.
• W2946988148 cites W2898370460 @default.
• W2946988148 cites W2898452483 @default.
• W2946988148 cites W2898564525 @default.
• W2946988148 cites W2904668994 @default.
• W2946988148 cites W2922107046 @default.
• W2946988148 cites W2925446385 @default.
• W2946988148 cites W4233387073 @default.
• W2946988148 cites W4243126678 @default.
• W2946988148 cites W4249552602 @default.
• W2946988148 cites W4252780045 @default.
• W2946988148 doi "https://doi.org/10.1016/j.lungcan.2019.05.027" @default.
• W2946988148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31319991" @default.
• W2946988148 hasPublicationYear "2019" @default.
• W2946988148 type Work @default.
• W2946988148 sameAs 2946988148 @default.
• W2946988148 citedByCount "28" @default.
• W2946988148 countsByYear W29469881482019 @default.
• W2946988148 countsByYear W29469881482020 @default.
• W2946988148 countsByYear W29469881482021 @default.
• W2946988148 countsByYear W29469881482022 @default.
• W2946988148 countsByYear W29469881482023 @default.
• W2946988148 crossrefType "journal-article" @default.
• W2946988148 hasAuthorship W2946988148A5006433317 @default.
• W2946988148 hasAuthorship W2946988148A5009144321 @default.
• W2946988148 hasAuthorship W2946988148A5012748795 @default.
• W2946988148 hasAuthorship W2946988148A5046566606 @default.
• W2946988148 hasAuthorship W2946988148A5080668859 @default.
• W2946988148 hasAuthorship W2946988148A5082061757 @default.
• W2946988148 hasAuthorship W2946988148A5087116862 @default.

• next